Autologous Stem Cell and Non-Stem Cell Based Therapies market is expected to grow throughout the forecast period owing to the introduction of novel autologous stem cell based therapies in regenerative medicine. These therapies do not involve usage of foreign organism cells like in the case of allografts and xenografts, thus, leading to a significant reduction in transplant associated risks of immune reactions, disease transmission and HLA incompatibility. Furthermore, the global growing prevalence of fatal neurodegenerative, cardiovascular and cancer diseases is further expected to fuel the growth of this market.
The market segmentation for the autologous stem cell and non-stem cell based therapies market is done on the basis of their applications in treating neurodegenerative, autoimmune, cardiovascular disorders, skin transplant, oncology and other infectious diseases. Autologous stem cell therapeutic applications for skin transplant accounted for the highest market share in terms of revenue owing to the fact that these therapies have been successful in wound healing, as skin substitutes for skin burns and other cosmetic surgeries. It is expected that the constant R&D in neurodegenerative and cardiovascular therapeutic application using autologous stem cells will drive market demand through to 2020.
Geographically, the autologous stem cell and non-stem cell based therapies markets can be divided into North America, Europe, Asia Pacific and RoW. It was observed that in 2013, North America accounted for the highest share of revenue in the global market. The efficacy of treatments using autologous stem cells and their applications to keep a check on the spread of infectious diseases has been a prime factor responsible for its large share. Other factors like presence of sophistication healthcare infrastructure, favorable taxation policy and beneficial reimbursement scenario are expected to further fuel the growth of the North America region in the market throughout the forecast period.
The key companies participating in the autologous stem cell and non-stem cell based therapies market are Bioheart, Antrie, Virxsys, Brainstorm Cell Therapeutics, Tigenix, Cytori, Tengion, Dendreon Corporation, Regenexx, Regeneus, Fibrocell, Genesis Biopharma, Orgenesis, Opexa Therapeutics, Neostem and Georgia Health Science University. These market players are involved in R&D programs for novel applications of autologous stem cell therapies in various treatments especially the cardiovascular reconstructive procedures.
Avail customized purchase options to meet your exact research needs:
Get your queries resolved from an industry expert.
Design an exclusive study to serve your research needs.
A testimonial for service in the form of BBB "A" Accreditation.
Your personal and confidential information is safe and secure.
"The quality of research they have done for us has been excellent..."